Skip to main content

Shell announces pause in share buyback programme

Shell announces pause in share buyback programme June 12, 2026 Further to its May 7, 2026 announcement of the start of a $3.0 billion share buyback programme covering an aggregate contract term of approximately three months (the ‘programme’), Shell plc (the ‘Company’) today announces that, following publication of the ARC Resources Ltd. (“ARC”) shareholder circular and due to related securities law requirements that apply to the Company, the programme is suspended from, and including, June 12, 2026 until, and including, market close on July 14, 2026, being the published date of the ARC shareholder meeting. Any buybacks not undertaken due to such suspension will be part of the remaining 2026 programmes (subject to Board approval). The Company will provide a further update if the suspension extends beyond the dates set out herein. Enquiries: Media:...

Continue reading

MAX Power Announces Special Meeting of Shareholders and Completion of Warrant Exercise for Total Proceeds of $3.75 Million

Genesis Explained: Its “Salt Barrier” Advantage and Proximity To Demandhttps://www.youtube.com/watch?v=3ytpHdve6S8 REGINA, Saskatchewan, June 12, 2026 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FSE: 89N) (“MAX Power” or the “Company”) is pleased to announce that Big Energy, an affiliate of Vietnam-based Bitexco, has completed the exercise of its 8,333,333 share purchase warrants for total proceeds to MAX Power of $3.75 million. This early exercise of warrants increases Big Energy’s total common share position in MAX Power to 24,999,999, representing 14.5% of the current issued and outstanding shares of the Company. Mr. Ran Narayanasamy, MAX Power CEO, commented: “We’re delighted with Big Energy’s early exercise of these warrants as it underscores how they are aligned with our vision of immediately building...

Continue reading

Rezolve Ai Board Moves to Authorize Capital Reduction and Up to $300 Million Share Repurchase Program

Proposed authorities would provide capital allocation flexibility as the Company intends to commence repurchases, while evaluating further non-dilutive funding alternatives for long-term shareholder value NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), (“Rezolve Ai” or the “Company”), a global leader in AI-powered commerce, today announced that its Board of Directors will seek authority at the Company’s upcoming annual general meeting to be held on June 30, 2026, to approve a capital reduction and an agreement with BTIG, a global financial services firm, enabling the Company to repurchase up to $300 million of ordinary shares. The proposed program reflects the Board’s confidence in Rezolve Ai’s long-term prospects and its belief that the Company’s current public market valuation does not reflect the strength...

Continue reading

Park Ha Biological Technology Co., Ltd. announces strategic partnership with Star Plus Legend Group’s wholly-owned subsidiary to build an AI-powered skincare and health ecosystem and expand its healthcare reach

Wuxi, China, June 12, 2026 (GLOBE NEWSWIRE) — Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that the Company has established a comprehensive strategic partnership with Star Plus Action (HK) Limited (“Star Plus Action”), a wholly-owned subsidiary of Star Plus Legend Holdings Limited (6683.HK), a company listed on The Stock Exchange of Hong Kong (“Star Plus Legend”). The two parties will integrate resources in the healthcare industry, skincare product development, celebrity IP management, and artificial intelligence technology to jointly advance the beauty and wellness sector, creating an innovative business model that combines AI technology, professional skincare services, and health maintenance. Their first collaborative smart product—the AI Nutritionist—has been launched...

Continue reading

OFA Group Receives Additional 180-Day Nasdaq Compliance Period; Nasdaq Confirms Company Remains Compliant with All Continued Listing Standards Other Than the Minimum Bid Price Requirement

Torrance, California, June 12, 2026 (GLOBE NEWSWIRE) — OFA Group (Nasdaq: OFAL) (“OFA” or the “Company”) today announced that it has received notice from the Nasdaq Listing Qualifications Department granting the Company an additional 180-calendar-day period, through December 7, 2026, to regain compliance with the minimum $1.00 bid price per share requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s determination to grant the second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the bid price requirement being the sole exception, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting...

Continue reading

KE Holdings Inc. Announces Results of Annual General Meeting

BEIJING, June 12, 2026 (GLOBE NEWSWIRE) — KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of annual general meeting dated April 24, 2026 has been adopted at the meeting held in Beijing, China today. After the adoption of the Proposed Resolutions, all corporate authorizations and actions contemplated thereunder were approved, including, among other things, that (i) the Company’s existing memorandum and articles of association are amended and restated by their deletion in their entirety and by the substitution in their place of the seventh amended and restated memorandum and articles...

Continue reading

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

– JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors – – Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 – WALTHAM, Mass. and BOULDER, Colo., June 12, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential best-in-class JAK2 V617F mutant-selective inhibitor in a poster presentation at the 2026 European Hematology Association (EHA) Congress taking place in Stockholm, Sweden, June 11-14, 2026. “We’re encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today,” said Andrew Robbins,...

Continue reading

Decisions of the Repeated Annual General Meeting of Shareholders of AB “Novaturas”

On 12 June 2026 a Repeated Annual General Meeting of Shareholders (hereinafter – the Repeated Meeting) of AB Novaturas, code 135567698, with its registered office at A. Mickevičiaus st. 27, Kaunas, the Republic of Lithuania (hereinafter – the Company) took place. The Repeated Meeting adopted the following decisions: 1. The Company’s consolidated management report for 2025. No decision has been taken on this item.  2. The independent auditor’s report on the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. No decision has been taken on this item.  3. Approval of the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. To approve the Company’s audited annual financial statements and the Company’s consolidated financial statements...

Continue reading

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026. Presentation DetailsFormat: Fireside ChatDate: Monday, June 15, 2026Time: 7:00 – 7:30 AM ETWebcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate,...

Continue reading

Exodus Launches Exodus Markets for Tokenized Assets with Ondo Finance

The partnership gives Exodus customers one-tap access to trading 200+ tokenized stocks and ETFs OMAHA, Neb., June 12, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”) today announced the launch of Exodus Markets in partnership with Ondo Finance, a leader in tokenized assets, giving customers the ability to buy and sell more than 200 tokenized stocks, ETFs, and real-world assets directly on Solana through Exodus. Exodus Markets is the latest step in Exodus’ expansion from a self-custodial wallet into a complete financial platform that lets customers trade, spend, send, earn rewards, and manage money in one app. “Tokenized stocks are one of the most important developments in modern finance,” said JP Richardson, CEO and Co-founder of Exodus. “For the first time, our customers can trade and hold...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.